What is the current level of GAAP and non‑GAAP earnings per share, and how do they compare to consensus estimates? | PSNL (Aug 06, 2025) | Candlesense
PSNL

What is the current level of GAAP and non‑GAAP earnings per share, and how do they compare to consensus estimates?

Answer

The excerpt you provided from Personalis Inc.’s (NASDAQ: PSNL) second‑quarter 2025 press release focuses on operational highlights—specifically the number of clinical tests performed and the acceleration of physician adoption of the NeXT Personal¼ platform. It does not include any figures on:

  • GAAP earnings per share (EPS)
  • Non‑GAAP earnings per share (EPS)
  • How either GAAP or non‑GAAP EPS compares to Wall‑Street consensus estimates

Because those earnings‑per‑share details are absent from the supplied summary, I can’t give you the current GAAP or non‑GAAP EPS values, nor explain how they stack up against analysts’ expectations.

What to do next

To obtain the requested information, you’ll need to locate the full press release (or the accompanying investor presentation) that Personalis issued on August 5 2025. Those documents typically contain a “Financial Results” table that lists:

Metric Q2 2025 (GAAP) Q2 2025 (Non‑GAAP) Consensus Estimate (GAAP) Consensus Estimate (Non‑GAAP)

If you can access the complete release (often posted on Business Wire, the company’s investor‑relations website, or the SEC’s EDGAR system), you’ll be able to extract the exact EPS numbers and see whether they beat, missed, or matched analyst forecasts.

In short: Based solely on the information you shared, the current GAAP and non‑GAAP earnings per share and their comparison to consensus estimates are not available. Please refer to the full Personalis Q2 2025 earnings announcement for those details.

Other Questions About This News

What is the net revenue growth rate year-over-year for Q2 2025 and how does it compare to analyst expectations? What is the forward-looking guidance for revenue and earnings in the next quarter and FY 2025? What is the contribution margin and overall profitability of the NeXT Personal¼ platform in Q2 2025? What were the underlying drivers of the increase in clinical test volume (e.g., new contracts, pricing changes, new product adoption)? How does the Q2 2025 cash burn and cash runway compare to prior quarters and what is the updated cash runway outlook? How does the 59% sequential increase in clinical tests compare to prior quarters and to the company's historical growth rates? How have recent macro‑economic factors (e.g., reimbursement policy changes, healthcare spending trends) impacted the outlook? What is the expected impact of potential dilution from future equity issuances or convertible debt? What technical or competitive risks could affect the sustainability of the 59% test volume growth? What is the status of the “Win‑in‑MRD” strategy and its potential impact on future market share and pricing power? Are there any regulatory approvals, FDA clearances or reimbursement updates that could affect future revenue? How does Personalis’ performance compare with other precision oncology and genomics companies (e.g., Illumina, Guardant Health, Invitae) in terms of test volume and revenue growth? What are the trends in operating expenses, R&D and SG&A, and how are they impacting profitability? What guidance does management provide regarding the timeline and scalability of the NeXT Personal¼ platform? What is the composition of the customer base (e.g., number of hospital/clinical partners) and its concentration risk? What are the anticipated impacts of any recent partnership or licensing agreements on future revenue and margins?